TrialCell transplantation

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.

Dong Won Baek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.